Journal of Clinical Oncology
Articles in this Issue
Medicare plan switching, hospice enrollment, and place of hospice services at the end-of-life among decedent patients diagnosed with distant stage cancers in 2010-2019.
11089 Background: Prior studies showed higher hospice utilization among Medicare Advantages (MA) than among Traditional Medicare (TM) beneficiaries. With...
Short-term pre-operative durvalumab (MEDI 4736) in early small triple-negative breast cancer patients (POP-Durva).
TPS623 Background: Pathological response to neoadjuvant immune checkpoint inhibitors (ICI) is associated with excellent survival in several tumor types. I...
Big data analysis of outcomes in non-small cell lung cancer at a regional cancer institute with a coordinated precision medicine program.
e15161 Background: Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases, and the 5-year survival rate for patients w...
Cadonilimab in combination with ivonescimab and chemotherapy as first-line (1L) therapy in patients with advanced gastric (G) or gastroesophageal junction adenocarcinoma (GEJA).
e16037 Background: Cadonilimab (AK104), an anti-PD-1/CTLA-4 bispecific antibody, plus chemotherapy (chemo) significantly improved OS versus chemo and had...
Prognostic factors and outcomes in patients with hematological malignancies developing therapy-related acute myeloid leukemia.
e24037 Background: Patients (pts) with chronic lymphocytic leukemia (CLL), lymphomas (L), and multiple myeloma (MM) are at increased risk of second primar...
Non-Hodgkin lymphomas in a Turkish pediatric cancer center: A developing-country model.
e22002 Background: This study aimed to evaluate the diagnostic findings and treatment outcomes of our pediatric non-Hodgkin’s lymphoma cases, gain a bette...
Dual targets, singular promise: A comprehensive analysis of bispecific antibodies in solid tumor oncology.
e14505 Background: Bispecific Antibodies (BsAbs) represent a novel class of immunoglobulins that can target and bind to two distinct antigens simultaneous...
Mapping policy effects: The influence of Medicaid expansion on geospatial hotspots of incidence and late-stage breast cancer in Indiana.
e23049 Background: Expansion of Medicaid eligibility has been associated with earlier-stage breast cancer diagnoses, but it remains unclear whether this a...
The benefit of cytoreductive surgery during imatinib (IM) therapy in patients with metastatic gastrointestinal stromal tumors (mGISTs): Retrospective analysis from several cancer centers.
11523 Background: the role of cytoreductive surgery for patients with mGISTs during IM therapy has not been established yet because the absence of randomi...
Interferon signaling and outcomes in triple-negative breast cancer (TNBC) in FinXX, CALGB 40603 (Alliance) and real-world clinico-genomic data.
569 Background: Several studies established the prognostic role of both the amount and locations of tumor-infiltrating lymphocytes (TILs) in TNBC. Three d...
TP53 mutation as a prognostic factor in metastatic non-small cell lung cancer (NSCLC): A retrospective review.
e20506 Background: TP53 is one of the most commonly mutated genes found in all cancers including NSCLC. We assessed prevalence of TP53 mutation in patient...
A phase I study of adoptive tumor-infiltrating lymphocyte (TIL, BST02) therapy in patients with advanced liver cancer.
e16198 Background: Liver cancer (LC) is the leading cause of cancer-related death in patients around the world. Treatment options for advanced LC are limi...
Patient-reported outcomes (PROs) in locally advanced cervical cancer (LACC): Insights from the OUTBACK trial.
5503 Background: OUTBACK (ACTRN12610000732088), an open-label, international, randomized phase 3 trial of 919 participants (pts) with LACC, showed that ad...
Management of oligoprogressive EGFR+ NSCLC in the age of osimertinib: A single center experience.
e20656 Background: Oligoprogressive disease (OPD), often defined as <5 progressing lesions, is common in patients with EGFR+ NSCLC who progress while r...
Adjuvant therapy after neoadjuvant immunotherapy combined with chemotherapy in locally advanced resectable esophageal squamous cell carcinoma: A retrospective study study.
e16152 Background : In esophageal squamous cell carcinoma (ESCC), neoadjuvant immunotherapy combined with chemotherapy followed by surgery (NI...
Validation of the performance of Ovarian Cancer Score for diagnosing ovarian cancer in a multicenter study.
5550 Background: Early detection is crucial for improving survival of patients with ovarian cancer (OC), yet current diagnostic tools lack adequate sensit...
Induction of neoantigen-specific immune responses by VB10.NEO in combination with atezolizumab in heavily pretreated patients with advanced solid tumors: Final analysis of the phase 1b VB N-02 trial.
2639 Background: VB10.NEO, a personalized DNA-based neoantigen vaccine, was evaluated with atezolizumab in a Phase 1b trial to assess safety, clinical act...
Evaluating the role of preoperative plasma insulin-like growth factor 1 (IGF-1) as a predictor of survival and recurrence in patients with resectable hepatocellular carcinoma.
e16318 Background: Low serum Insulin-like Growth Factor 1 (IGF-1) levels are associated with multinodularity, and shorter overall survival (OS) in patient...
Analysis of mutational profiles and their correlation with organ-specific metastases in MSS and <i>BRAF</i> wt colorectal cancer (mCRC).
3556 Background: In BRAF wt/ MSS mCRC, the mechanisms driving distinct metastatic dissemination patterns remain unclear. Understan...
CD123 expression and its correlation with mutation profile in acute myeloid leukemia.
e18524 Background: CD123, the interleukin-3 receptor α-chain, is frequently overexpressed by acute myeloid leukemia (AML) blasts and may represent a poten...
Financial burden and financial toxicity in cancer patients: A sub-analysis from a Brazilian prospective cohort.
11132 Background: Financial toxicity during cancer treatment can impact patients’ quality of life (QoL), adherence, and survival. Identifying subgroups wi...
Disparities in guideline-concordant treatment receipt for localized prostate cancer (PCa): A SEER-based analysis.
e17155 Background: Localized PCa is classified into six NCCN risk categories, each with specific treatment recommendations. However, treatment concordance...
A supervised prehabilitation program for patients with pancreatic cancer.
TPS4235 Background: Individuals who develop pancreatic cancer tend to be older, with 70% of pancreatic diagnoses occurring in those ≥ 65 years (2). Older...
Rectal arterial infusion chemotherapy combined with anti-PD1 antibody for microsatellite stable locally advanced rectal cancer: The effectiveness and safety of a single-arm, phase II study.
e15660 Background: The standard neoadjuvant therapy for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (nCRT). Nevertheless, nCRT...
Investigating the role of LRP1B in chemo-resistance in advanced triple-negative breast cancer.
e13150 Background: Advanced triple-negative breast cancer is usually chemo-resistant with high mortality. We aimed to develop novel therapeutic strategies...